A meta-analysis revealed that polymorphisms in ERCC1, GSTs, TS, and MTHFR were closely associated with clinical outcomes in GC patients treated with platinum/5-FU-based chemotherapy [8]. This evidence concerns the gene MTHFR and gastric cancer.